title: Should clinical trials be approached differently for rare cancers?
authors.affiliation: Sansom Institute for Health Research, University of South Australia, P5-06e Playford Building, City East Campus, GPO Box 2471, Adelaide, SA 5001, Australia.
authors.forename: Ian
authors.initials: I
authors.lastname: Olver
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D035583:Rare Diseases / Q000628:therapy*; D012107:Research Design
keywords: Bayesian; PARP inhibitor; Phase I; Phase II; Phase III; chemotherapy; randomization; rare cancers; type I error; type II error